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http://dx.doi.org/10.1016/j.ccr.2012.08.014SUMMARYMolecular signatures have identified several subsets of diffuse large B cell lymphoma (DLBCL) and rational
targets within the B cell receptor (BCR) signaling axis. The OxPhos-DLBCL subset, which harbors the signa-
ture of genes involved in mitochondrial metabolism, is insensitive to inhibition of BCR survival signaling but
is functionally undefined. We show that, compared with BCR-DLBCLs, OxPhos-DLBCLs display enhanced
mitochondrial energy transduction, greater incorporation of nutrient-derived carbons into the tricarboxylic
acid cycle, and increased glutathione levels. Moreover, perturbation of the fatty acid oxidation program
and glutathione synthesis proved selectively toxic to this tumor subset. Our analysis provides evidence for
distinct metabolic fingerprints and associated survival mechanisms in DLBCL and may have therapeutic
implications.INTRODUCTION
Tumors often rewire their metabolism to ensure a steady supply
of intermediary metabolites for synthesis of new biomass, as
well as generation of ATP and reducing equivalents (Barger
and Plas, 2010; DeBerardinis et al., 2008; Tennant et al., 2010).
This metabolic reprogramming is a dynamic process shaped
by oncogenes and tumor suppressors (Barger and Plas, 2010;Significance
B cell receptor (BCR) survival signals are central to pathoge
groups of DLBCL, the ‘‘OxPhos’’ subset displays increased ex
phorylation but lacks an intact BCR signaling network, sug
However, the functional basis of the OxPhos signature has not
fully dissected the patterns of fuel utilization and energy me
subset. We show that fatty acid oxidation and glutathione sy
selectively required for their survival. Metabolic signatures may
of DLBCL and reveal rational targets in these lymphomas.
CMorrish et al., 2008; Yuneva et al., 2012). One of the first meta-
bolic alterations identified in tumors is elevated glycolysis,
even in the presence of sufficient oxygen. This program, also
known as the Warburg effect or aerobic glycolysis, fulfills impor-
tant biosynthetic needs (Barger and Plas, 2010; Koppenol et al.,
2011; Vander Heiden et al., 2009). The Warburg effect has often
been interpreted as an indication of impaired mitochondrial
respiration (Koppenol et al., 2011). However, the relevance ofnesis of certain DLBCLs. Among transcriptionally defined
pression of genes involved in mitochondrial oxidative phos-
gesting dependence on alternative survival mechanisms.
been defined. Using an integrative approach, we have care-
tabolism in DLBCL, with a primary focus on the ‘‘OxPhos’’
nthesis are distinct metabolic features of OxPhos-DLBCLs
provide important insights into the molecular heterogeneity
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Metabolic Fingerprints in DLBCL Molecular Subsetsmitochondrial respiration in tumors is varied depending on tumor
type, and evidence for an oxidative class of tumors and tumors
with dual capacity for glycolytic and oxidative metabolism exists
(Marin-Valencia et al., 2012; Moreno-Sa´nchez et al., 2009).
Moreover, the importance of mitochondria in tumor cell survival
and proliferation, including utilization of alternative oxidizable
substrates such as glutamine and fatty acids, has been increas-
ingly appreciated (Le et al., 2012; Rossignol et al., 2004; Zaugg
et al., 2011). The diversity of carbon substrate utilization path-
ways in tumors is indicative of metabolic heterogeneity that
may not only be relevant across different types of cancer but
also manifest within a group of tumors that otherwise share
a common diagnosis.
Diffuse large B cell lymphomas (DLBCLs) are a genetically
heterogeneous group of tumors and the most common non-
Hodgkin’s lymphomas in adults (Abramson and Shipp, 2005;
Lenz and Staudt, 2010). However, the spectrum of fuel utilization
pathways and the metabolic fingerprints within DLBCL and
other similarly heterogeneous groups of tumors have not been
fully elucidated. To date, efforts to capture the molecular hetero-
geneity of DLBCL have relied on gene expression profiling that
has uncovered coordinate signaling and survival paradigms in
distinct subsets of DLBCL. In one approach, comparison of the
genetic signatures across DLBCLs using genome-wide arrays
and multiple clustering algorithms captured tumor-intrinsic
distinctions in three separate and reproducible clusters (Monti
et al., 2005). Groups of DLBCLs identified by this consensus
cluster classification (CCC) scheme are the B cell receptor
(BCR)/proliferation cluster (BCR-DLBCL) displaying upregu-
lation of genes encoding BCR signaling components, the
OxPhos cluster (OxPhos-DLBCL), which is significantly enriched
in genes involved in mitochondrial oxidative phosphorylation
(OxPhos), and the host response (HR) tumors largely character-
ized by a brisk host inflammatory infiltrate (Monti et al., 2005).
Another classification framework known as cell of origin (COO)
delineated DLBCL subsets that shared components of their
transcriptional profiles with normal B cell subtypes, including
germinal center B cell (GCB)-like and activated B cell (ABC)-
like (Alizadeh et al., 2000), and a third undefined category,
designated ‘‘type 3’’ (Wright et al., 2003). CCC and COO
classifications capture largely different molecular aspects of
DLBCL (Monti et al., 2005).
Unlike tumors that rely on signaling pathways downstream of
the BCR, OxPhos-DLBCLs do not display active/functional
BCR signaling (Chen et al., 2008). However, the nature of survival
pathways in this group of tumors is not known, and beyond
the original CCC assignment, the actual functional attributes of
the OxPhos molecular signature have not been fully examined.
This signature includes multiple subunits of mitochondrial
respiratory chain complexes I (NADH dehydrogenase) and V
(mitochondrial ATP synthase) that may suggest alterations in
mitochondrial energy transduction. However, given the inte-
grative aspect of cellular metabolism and the requirement
of both nuclear and mitochondria-encoded genes for proper
functioning of the electron transport machinery, the precise
metabolic landscape of this molecular subset could not be
predicted.
In the present study, we conducted an integrative analysis to
dissect the metabolic fingerprints of DLBCL and to delineate548 Cancer Cell 22, 547–560, October 16, 2012 ª2012 Elsevier Inc.subtype-specific differences that may selectively contribute to
the growth and survival of DLBCL subsets.
RESULTS
Subtype-Specific Differences in the DLBCL
Mitochondrial Proteome
The upregulation of select genes encoding for subunits of
electron transport chain (ETC) complexes in OxPhos-DLBCLs
predicts potential differences in mitochondrial oxidative metab-
olism compared with other DLBCL groups. However, as ETC
activity is linked to the supply of carbon substrates and reducing
equivalents, the OxPhos signature is likely part of a broader
spectrum of changes in mitochondrial nutrient metabolism that
may shed light on the actual functional attributes of an ‘‘OxPhos’’
program in this DLBCL subset. To search for additional com-
ponents of this metabolic program, we initially performed
two-dimensional differential gel electrophoresis (2D-DIGE) to
compare the proteome of mitochondria purified from represen-
tative OxPhos- and BCR-DLBCL cell lines Karpas 422 and
OCI-Ly1, respectively (Chen et al., 2008). Mitochondrial proteins
that wereR2.5 timesmore abundant in theOxPhos cell line were
identified by mass spectrometry (Figure S1A available online).
Among 2D-DIGE candidates were subunits of mitochondrial
respiratory chain complex I (NADH dehydrogenase), complex II
(succinate dehydrogenase, also a tricarboxylic acid [TCA] cycle
enzyme), complex V (ATP synthase), subunits of the pyruvate
dehydrogenase (PDH) complex and several other TCA cycle
enzymes, mitochondrial reactive oxygen species (ROS) detoxifi-
cation enzyme manganese superoxide dismutase (MnSOD or
SOD2), and enzymes involved in mitochondrial b-oxidation of
fatty acids and metabolism of ketone bodies and amino acids
(Figure S1A).
We next set out to interrogate the mitochondrial protein
signature defined by 2D-DIGE in a larger panel of OxPhos-
and BCR-DLBCL cell lines. This required an independent pro-
teomics approach amenable to multiplexing—isobaric tags for
relative and absolute quantification (iTRAQ) (Figure S1B) (Choe
et al., 2007; Ross et al., 2004)—for simultaneous quantitative
comparison of multiple unique tryptic peptides per candidate
mitochondrial protein across three pairs of OxPhos- and BCR-
DLBCL cell lines. This analysis confirmed significant quantitative
enrichment of mitochondrial b-oxidation enzymes and multiple
subunits of respiratory chain complexes, as well as TCA cycle
enzymes andMnSOD in OxPhos-DLBCLmitochondria (Figure 1;
Table S1).
Beyond confirming the differential expression of complex I
and V components that were in the original OxPhos-DLBCL
cluster signature (Monti et al., 2005), the 2D-DIGE and iTRAQ
proteomic analyses identified additional components of the
OxPhos-DLBCL mitochondrial signature that were not fully
captured by the previous RNA profile analysis of total tumors.
To examine whether these observations could also be substan-
tiated in primary OxPhos-DLBCLs, we examined tumor biopsies
for differences in the abundance of these newly identified
components of the mitochondrial signature at both protein and
RNA levels. The small en bloc primary DLBCL biopsies pre-
cluded isolation of tumor mitochondria; however, iTRAQ-based
quantification in a limited number of primary cases that
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Figure 1. Comparison of Mitochondrial Proteome in OxPhos- and BCR-DLBCLs
(A and B) Multiplex iTRAQ analysis of mitochondria derived from three OxPhos- (Karpas 422, Toledo, and Pfeiffer) and three BCR- (OCI-Ly1, SU-DHL-4, and SU-
DHL-6) DLBCL cell lines. Log-log plots of reporter ion abundance ratios versus reporter ion intensities for proteins detected in replicate nanoflow LC-MS/MS
analyses are shown in (A). Proteins within the mitochondrial signature that are enriched in OxPhos-DLBCLs are shown as red circles in (A) and grouped per
metabolic pathway in (B). Red lines in (A) represent global thresholds based on a ±1.5-fold change between OxPhos and BCR subtypes.
See also Figure S1 and Table S1.
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Metabolic Fingerprints in DLBCL Molecular Subsetsproduced protein samples of suitable purity and grade for liquid
chromatography/tandem mass spectrometry (LC-MS/MS)
indicated increased expression of several TCA cycle and mito-
chondrial b-oxidation enzymes, as well as MnSOD (Table S1).
The RNA abundance for candidate components of the mito-
chondrial proteome signature was also queried in two extensive
primary DLBCL expression profile data sets (Lenz et al., 2008;
Monti et al., 2005) with CCC designations (Tables S2 and S3)
and found to be significantly higher in primary OxPhos- than in
BCR-DLBCLs in both data sets (Figure 2). These observations
confirm that the differences in mitochondrial signature identified
in DLBCL cell lines translate to primary tumor biopsies.
The functional categories of proteins in the OxPhos-DLBCL
mitochondrial signature predict differences in mitochondrial
handling of fatty acids and pyruvate, ETC activity, mitochondrial
energy production, and ROS content. We next set out to validate
each of these predictions.
Mitochondrial Substrate Oxidation in DLBCL Subsets
To assess potential differences in mitochondrial carbon
substrate utilization, mitochondrial oxygen consumption rate
(OCR) was measured in real time in the absence or presence
of exogenously added substrates such as glucose, glutamine,
and palmitate, using a panel of 3–4 independent OxPhos and
‘‘non-OxPhos’’ DLBCL cell lines. The non-OxPhos panel
included cell lines with knownCCC assignment as BCR-DLBCLs
(Polo et al., 2007) and COO classification as GCB-, ABC-, orCType 3-DLBCLs (Alizadeh et al., 2000; Wright et al., 2003)
(see Supplemental Experimental Procedures). Basal OCR in
response to exogenously supplied palmitate was significantly
higher in OxPhos-DLBCLs relative to non-OxPhos DLBCL cell
lines (no substrate [NS] versus palmitate; Figure 3A). Basal
OCR values per individual DLBCL cell line are shown in Fig-
ure S2A. The non-OxPhos DLBCLs displayed either no increase
in OCR or an increase that was significantly less than that
observed in the OxPhos-DLBCLs (Figures 3A and S2A). Notably,
the majority of palmitate-stimulated OCR in OxPhos-DLBCLs
was sensitive to the mitochondrial ATP synthase inhibitor
oligomycin, indicating that mitochondrial fatty acid oxidation
(FAO) in this setting is associated with ATP synthesis (Figures
3A and S2A). These observations provide quantitative evi-
dence for increased mitochondrial FAO in OxPhos-DLBCLs.
Analysis of other oxidizable substrates showed that none of
the DLBCL subsets respire on glucose (NS vs. glucose; Figures
3A and S2A). However, in response to glutamine, all DLBCL
subsets exhibited a comparable increase in basal and ATP-
associated (oligomycin-inhibitable) OCR (NS versus glutamine;
Figures 3A and S2A). Taken together, comparison of the three
carbon substrates across and within DLBCL subsets indicates
that palmitate is a predominant respiratory fuel in OxPhos-
DLBCLs.
A marked increase in palmitate-induced OCR in OxPhos-
DLBCL compared with non-OxPhos DLBCL cell lines parallels
the absence or presence of functional BCR signaling in theseancer Cell 22, 547–560, October 16, 2012 ª2012 Elsevier Inc. 549
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Figure 2. Increased Abundance of Transcripts Encoding Mitochondrial Proteins in Primary DLBCL Tumor Biopsies
(A) Heat map representation of the relative mRNA levels of genes corresponding to the components of themitochondrial proteome signature using theMonti et al.
(left) and Lenz et al. (right) expression array data sets of primary DLBCL cases with OxPhos and BCR consensus cluster assignments.
(B) Transcript abundance (probe intensity) of the indicated genes in primary OxPhos- and BCR-DLBCLs from the Monti et al. (top) and Lenz et al. (bottom) data
sets. Differential expression was determined by a two-sided Mann-Whitney test and p values were corrected for multiple hypothesis testing using the false
discovery rate (FDR) procedure.
NDUFA5, NADH dehydrogenase (ubiquinone) 1a subcomplex subunit 5; NDUFS3, NADH dehydrogenase (ubiquinone) Fe-S protein 3; ETFA, electron-transfer-
flavoprotein A; ACAT1, acetoacetyl-CoA thiolase 1; MTHFD2, methylenetetrahydrofolate dehydrogenase 2; SOD2, manganese superoxide dismutase.
See also Tables S2 and S3.
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Metabolic Fingerprints in DLBCL Molecular Subsetssubsets, respectively (Chen et al., 2008). This prompted exami-
nation of a potential reciprocal relationship between active
BCR signaling and mitochondrial FAO. Such a scenario would
predict that inhibition of BCR signaling in non-OxPhos/BCR
DLBCLs may manifest in increased mitochondrial FAO. Indeed,
acute interference with BCR signaling using multiple indepen-
dent shRNAs against SYK, an upstream component of this
signaling axis, was associated with significant elevation of
basal palmitate-induced OCR (Figure 3B). Notably, OCR mea-
surements were taken after 24 hr treatment with shRNAs, which
enabled sufficient depletion of SYK (Figure S2B) without
affecting cell viability (data not shown). These observations are
suggestive of an underlying metabolic plasticity that governs
the pattern of fuel oxidation in DLBCL subsets.
To provide independent and parallel evidence for differential
utilization of fatty acids in DLBCL subsets, a targeted 13C iso-
topomer approach was undertaken. A total of eight cell lines
with known designation as OxPhos or BCR were cultured in
media containing uniformly labeled 13C-palmitate (U13C-palmi-
tate), and 13C enrichment was assessed in a defined set of
intermediates derived from fatty acid metabolism. The complete
oxidation of 13C-palmitate by mitochondria yields eight acetyl
units that can donate carbons to the TCA cycle in the form
of citrate labeled on two carbons (13C2-citrate), which can, in
turn, lead to the formation of 13C2-a-ketoglutarate that is in550 Cancer Cell 22, 547–560, October 16, 2012 ª2012 Elsevier Inc.isotopic equilibriumwith 13C2-glutamate (Figure 4A). The relative
level of 13C enrichment in both 13C2-citrate and 13C2-glutamate
was significantly higher in the OxPhos-DLBCL cell lines (Fig-
ure 4B). This is consistent with greater entry of palmitate carbons
into the TCA cycle.
In addition to oxidative metabolism for energy production,
palmitate may have important biosynthetic roles, including
direct incorporation into phosphatidyl choline (PC) to yield
U13C-Palmitate-PC (Figure 4A). Alternatively, palmitate-derived
citrate can be exported from mitochondria and its carbons
subsequently incorporated into the head group of PC
(13C2-acetyl-PC; Figure 4A). In both DLBCL subtypes, direct
incorporation of palmitate into PC (U13C-palmitate-PC) was
observed. In addition, a larger enrichment of palmitate car-
bons in 13C2-acetyl-PC was detected in OxPhos cell lines
(Figure 4B).
A preferential increase in palmitate utilization in OxPhos-
DLBCLs prompted examination of its effect on proliferation
in these cells. Supplementation of serum-free media con-
taining amino acids with palmitate and carnitine led to a
modest but significant and selective increase in the prolifera-
tion of OxPhos-DLBCLs (Figure 4C). In the absence of
palmitate, carnitine, which is required for mitochondrial import
of long-chain fatty acids, did not influence proliferation
(Figure 4C).
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Figure 3. Mitochondrial Carbon Substrate Oxidation in DLBCL Subsets and Its Regulation by BCR Signaling
(A) Basal (left) and ATP-coupled (right) OCR in DLBCL subsets. OCR values shown are the average of all cell lines per DLBCL subtype indicated on top. For each
cell line, 7–13 independent OCR measurements were taken. NS, no substrate added exogenously.
(B) Palmitate-stimulated basal OCR in non-OxPhos DLBCL cell lines after acute knockdown of SYK.
Error bars, ±SEM. *p < 0.05; **p < 0.01; ***p < 0.001; two-tailed Student’s t test.
See also Figure S2.
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Metabolic Fingerprints in DLBCL Molecular SubsetsTo probe the prosurvival benefit of mitochondrial FAO
in DLBCL subsets, this program was inhibited using 4-bromoc-
rotonic acid (BrCA), which irreversibly inhibits mitochondrial
b-oxidation of both long- and short-chain fatty acids (el-Aleem
and Schulz, 1987). Acute treatment of DLBCL cell lines (4 hr)
with BrCA interfered with palmitate stimulation of basal OCR
in OxPhos-DLBCL cell lines (Figure S3), while longer treatment
(24 hr) was selectively toxic to this subset compared with
BCR-DLBCLs (Figure 4D). These results suggest that the
mitochondrial FAO program provides prosurvival benefits to
OxPhos-DLBCLs.
Programmatic Regulation of FAO and Its Relevance
to OxPhos-DLBCL Survival
The concomitant increase in the abundance of several mito-
chondrial FAO enzymes in OxPhos-DLBCLs is consistent, atCleast in part, with a programmatic increase in the transcriptional
regulation of this pathway. These observations warranted
systematic interrogation of the primary DLBCL transcript data
sets for the prevalence of a defined list of transcriptional regu-
lators of this pathway. Nuclear receptor peroxisome prolife-
rator-activated receptor (PPAR) g transcripts were found to
be significantly more abundant in primary OxPhos-DLBCLs in
two independent cohorts of DLBCL tumors (Figure S4A). This
is consistent with the observation that several enzymes identi-
fied in the mitochondrial protein signature of OxPhos-DLBCLs
such as ETF, ACAD, and HADH, as well as multiple subunits of
mitochondrial respiratory chain complexes I, II, and ATP syn-
thase, are downstream targets of PPARg (Hsiao et al., 2011).
To probe the functional relevance of PPARg in DLBCL subsets,
we tested the effect of its depletion using three independent
siRNAs and their corresponding mixture (Figures 5A and S4B).ancer Cell 22, 547–560, October 16, 2012 ª2012 Elsevier Inc. 551
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Figure 4. Palmitate Metabolism and Its Effect on DLBCL Proliferation and Survival
(A and B) 13C isotopomer analysis of uniformly labeled palmitate (U13C-Palmitate). (A) Schematics depicting the number of carbons labeled (filled circles) in
a defined set of metabolites derived from palmitate. Metabolites marked in red are selectively elevated in OxPhos-DLBCL cell lines in (B). (B) 13C enrichment in
palmitate-derived metabolites. For each metabolite, cumulative data obtained from all four OxPhos-DLBCL cell lines are shown relative to the mean value of that
metabolite in all four BCR-DLBCL cell lines listed on top.
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AB
Figure 5. Programmatic Regulation of FAO
and Its Relevance to DLBCL Survival
(A) Effect of siRNA-mediated depletion of PPARg
on the survival of DLBCL subsets.
(B) Survival of the indicated DLBCL cell lines
cultured in the absence or presence of increasing
concentrations of T0070907 for 96 hr.
Error bars, ±SEM. **p < 0.01; ***p < 0.001; two-
tailed Student’s t test.
See also Figure S4.
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Metabolic Fingerprints in DLBCL Molecular SubsetsThemost robust decrease in PPARg protein levels was achieved
using the siRNA mix (Figure S4C) and was accompanied by
significant apoptosis in OxPhos-DLBCLs compared with the
BCR subset (Figure 5A).
To provide a pharmacologic correlate to these findings, we
also tested the effect of two selective PPARg antagonists
T0070907 and GW9662 (Lee et al., 2002; Leesnitzer et al.,
2002). Short-term treatment of DLBCL cell lines with these
compounds blocked palmitate stimulation of OCR (data not
shown). Upon longer incubation periods (96 hr), these com-
pounds proved selectively toxic to OxPhos-DLBCLs (Figures
5B and S4D). The aforementioned genetic and pharmacologic
approaches to PPARg inhibition complement and extend the
results shown in Figure 4D that pharmacologic inhibition of
mitochondrial b-oxidation program is toxic to OxPhos-DLBCLs
and are collectively congruent with the idea that a sustained
mitochondrial FAO program may be relevant for the survival of
OxPhos-DLBCLs.(C) Effect of palmitate supplementation on the proliferation of DLBCL cell lines. Control denotes serum-free me
(D) Survival of DLBCL subsets cultured in the absence or presence of BrCA for 24 hr.
Error bars, ±SEM. *p < 0.05; **p < 0.01; ***p < 0.001; two-tailed Student’s t test.
See also Figure S3.
Cancer Cell 22, 547–560,Differential Utilization of Glucose-
Derived Carbons
in DLBCL Subsets
Identification of PDH as a component
of the mitochondrial proteome signature
in OxPhos-DLBCLs predicts differential
mitochondrial handling of pyruvate.
Indeed, biochemical analysis of isolated
mitochondria derived from a panel of
DLBCL cell lines indicated significant
increase in PDH enzyme activity in
OxPhos-DLBCLs (Figure 6A). Increased
PDH activity would further predict
diminished availability of glucose-derived
pyruvate for lactate synthesis. Biochem-
ical quantification of glucose-derived
lactate secreted by OxPhos-DLBCL cell
lines compared to non-OxPhos/BCR
counterparts indicated that this is
indeed the case (Figure 6A). These ob-
servations prompted a more detailed
examination of the fate of glucose
carbons in DLBCL subsets.Beyond generation of pyruvate, glucose-derived metabolites
are central to several biosynthetic pathways (Figure 6B). For
example, glucose-6-phosphate can enter the pentose phos-
phate pathway to yield ribose sugars for nucleic acid synthesis
and NADPH generation for lipid synthesis and ROS detoxi-
fication (Tennant et al., 2010; Vander Heiden et al., 2009).
Dihydroxyacetone phosphate, which is in equilibrium with
glyceraldehyde-3-phosphate, is used in glycerol synthesis,
providing a necessary backbone for membrane phospholipids.
Finally, glucose-derived citrate and aspartate, a surrogate for
oxaloacetate (OAA), can be used in lipid and nucleotide syn-
thesis, respectively. To examine differences in the terminal fate
of glucose-derived pyruvate and the branch points at which
glucose carbons divert to biosynthetic pathways in different
DLBCL subsets, we carried out a targeted 13C isotopomer anal-
ysis using uniformly labeled 13C-glucose (U13C-glucose).
Glucose uptake was comparable in DLBCL cell lines as
evident from the similar levels of remaining U13C-glucose in thedia containing all amino acids except L-glutamine.
October 16, 2012 ª2012 Elsevier Inc. 553
A B
La
ct
at
e 
(n
m
ol
es
)
P
D
H
 A
ct
iv
ity
 (m
O
D
/m
in
) 
C
***
***
0
0.5
1.0
1.5
0
0.5
1.0
1.5
0
0.5
1.0
1.5
0
0.5
1.0
1.5
0
0.5
1.0
1.5
0
0.5
1.0
1.5
0
0.5
1.0
1.5
0
0.5
1.0
1.5
0
0.5
1.0
1.5
U13C-Glucose-6
-Phosphate U13C-Pentose 13C-Glycerol-PC
U13C-Glucose
in Media
U13C-Alanine
(Intracellular)
U13C-Lactate
(Intracellular)
13C2-Glutamate13C2-Citrate 13C2-αketoglutarate13C2-Acetyl-PC
** ***
** *
**
0
0.5
1.0
1.5
2.0
13C2-Aspartate
*
0
0.5
1.0
1.5
0
0.5
1.0
1.5
U13C-Lactate
(Extracellular)
U13C-Alanine
(Extracellular)
**
**
R
el
at
iv
e 
13
C
 E
nr
ic
hm
en
t
R
el
at
iv
e 
13
C
 E
nr
ic
hm
en
t
R
el
at
iv
e 
13
C
 E
nr
ic
hm
en
t
0
5
10
15
20
25
**
*
C
Y
TO
P
LA
S
M
M
IT
O
C
H
O
N
D
R
IO
N
U13C-Glucose-6-Phosphate
U13C-Glyceraldehyde-3-Phosphate
13C3-Pyruvate
U13C-Alanine U13C-Lactate
13C2-Acetyl-CoA
U13C-Pentose
13C2-Citrate
U13C-Glucose
13C-Glycerol-PC
PC
13C-Acetyl-PC
PC
U13C-Alanine U13C-Lactate
PDH
13C2-αketoglutarate
13C2-Glutamate
13C2-Citrate
13C2-OAA
13C2-Aspartate
0
0.5
1.0
1.5
2.0 ***
OxPhos BCR 
0
0.5
1.0
1.5
2.0
2.5
3.0
non-ABC 
SU-DHL-4
SU-DHL-6
OCI-Ly1
OCI-Ly7
Karpas 422
OCI-Ly4
Pfeiffer
Toledo
ABC
OCI-Ly3
OCI-Ly10
HBL-1
U2932
Figure 6. Utilization of Glucose-Derived Carbons in DLBCL Subsets
(A) PDH enzyme activity (middle) and lactate production from glucose (bottom) in DLBCL subsets. Data are cumulative from independent DLBCL cell lines listed
on top.
(B and C) 13C isotopomer analysis of uniformly labeled glucose (U13C-glucose) (B) Schematics depicting the number of carbons labeled (filled circles) in
intermediary metabolites of glucose metabolism. (C) 13C enrichment in glucose-derived metabolites. For each metabolite, cumulative data obtained from all
four OxPhos-DLBCL cell lines (Karpas 422, OCI-Ly4, Pfeiffer, and Toledo; red bars) are shown relative to the mean value of that metabolite in all four BCR-DLBCL
cell lines (SU-DHL-4, SU-DHL-6, OCI-Ly1, and OCI-Ly7; black bars).
Error bars, ±SEM. *p < 0.05; **p < 0.01, ***p < 0.001; two-tailed Student’s t test.
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Metabolic Fingerprints in DLBCL Molecular Subsetsmedia following 8 hr incubation (Figure 6C). The BCR cell lines
displayed a larger contribution of glucose-derived carbons to
the synthesis of pentose sugars compared with the OxPhos
cell lines (U13C-pentose; Figure 6C). This is consistent with
reduced levels of U13C-glucose-6-phosphate precursor ob-
served in this subset (Figure 6C), provided that the oxidative
branch of the pentose phosphate pathway is utilized to derive
pentose sugars. In addition, the contribution of glucose carbons
to glycerol incorporation into PC was significantly higher in
BCR cell lines (13C-glycerol-PC; Figure 6C).
The overall glycolytic capacity was assessed by comparing
both intracellular and extracellular (secreted) U13C-lactate and
U13C-alanine (a surrogate for pyruvate). BCR cell lines had sig-
nificantly higher intracellular and secreted U13C-alanine and
U13C-lactate (Figure 6C). These data are consistent with bio-
chemical evidence that glucose-derived lactate is higher in
these cells (Figure 6A), suggesting a higher glycolytic flux.
Glucose-derived pyruvate can enter the TCA cycle through
a PDH-catalyzed reaction yielding citrate or through a pyru-
vate-carboxylase-mediated anaplerotic reaction that generates
OAA (Fan et al., 2009). The ratio of PDH and pyruvate carbox-
ylase activities in tumors is variable (DeBerardinis et al., 2007;
Fan et al., 2009), suggesting significant diversity and tumor
type specificity in the mode of TCA cycle entry of glucose-
derived carbons. The PDH reaction can be traced by the pattern
of carbon labeling in citrate as 13C2-citrate. The relative 13C
enrichment in this metabolite was significantly higher in OxPhos
cell lines (Figure 6C), indicating a greater overall diversion of
glucose carbons to the TCA cycle. Elevated PDH-catalyzed
formation of 13C2-citrate in OxPhos-DLBCLs is consistent with
increased levels of PDH and enzyme activity in this subset.
Among other TCA cycle intermediates measured in this analysis,
13C enrichment in aspartate (surrogate for OAA) was relatively
higher in OxPhos compared with BCR cell lines (13C2-aspartate;
Figure 6C).
Despite elevated PDH activity in OxPhos-DLBCLs and higher
enrichment of glucose carbons in the aforementioned TCA
cycle intermediates, glucose is not fully oxidized to stimulate
mitochondrial OCR in these cells (Figures 3A and S2A). This
may be due to greater diversion of glucose-derived TCA inter-
mediates to biosynthetic pathways. Overall, the distinct enrich-
ment patterns of carbons in glucose-derived metabolites
indicate relative diminution of lactate production in OxPhos-
DLBCL and an attendant increase in the entry of glucose
carbons in the TCA cycle via citrate.
Contribution of Mitochondrial Metabolism to Cellular
ATP Budget in DLBCL Subsets
The observed differences in utilization of palmitate- and glucose-
derived carbons, as well as ATP generation through mito-
chondrial oxidation of palmitate (ATP-coupled respiration) in
DLBCL subsets, warranted comparison of mitochondrial and
nonmitochondrial contributions to the cellular energy budget.
To this end, the portion of total cellular ATP that is sensitive to
inhibition of glycolysis versus mitochondrial metabolism was
assessed (Guppy et al., 2002). Compared to BCR-DLBCL, the
OxPhos subset derives a significantly higher portion of its total
energy (70%) from mitochondrial oxidative metabolism than
from glycolysis (Figure 7A). The higher contribution of mitochon-Cdria to total cellular ATP in OxPhos-DLBCLs is concordant with
increased expression of mitochondrial ATP synthase (complex
V) subunits (Figures 1 and S1A; Table S1) and an elevated rate
of mitochondrial ATP synthesis in OxPhos-DLBCL cell lines (Fig-
ure 7B). These observations could be potentially explained by
differences in mitochondrial content in DLBCL subtypes.
However, assessment of the steady-state content of mitochon-
dria in DLBCL cell lines did not reveal any subtype-specific
differences (Figure S5A). In addition, mitochondrial SNP copy
number analysis in a cohort of primary biopsies with OxPhos
or BCR assignments did not reveal any differences (Figure 7C).
Increased contribution of mitochondria to total cellular ATP
may reflect not only distinct channeling of carbon substrates in
mitochondria but also differential activity or efficiency of mito-
chondrial ETC complexes. Studies in isolated mitochondria
derived from DLBCL cell lines enabled direct assessment of
mitochondrial respiration at the organelle level independent of
the cytosolic processing of carbon substrates.
Mitochondrial respiratory states were assessed using gluta-
mate/malate and succinate as complex I- and II-linked
substrates, respectively (Figures 7D and 7E). When measuring
complex II activity, rotenone was included with succinate to
inhibit the reverse flow of electrons to complex I. Respiratory
rates in the presence of substrate alone (also known as state II
respiration) were higher in OxPhos-DLBCL mitochondria (Fig-
ure 7F). The addition of ADP, which mimics a state of energy
demand driving high rates of respiration (also known as state
III respiration) elicited significantly higher OCR in OxPhos-
DLBCL mitochondria supplied with either complex I or II
substrates (Figure 7F). This increased respiration is used for
ATP synthesis and is sensitive to oligomycin. Accordingly,
OCR values in the presence of substrate, ADP and oligomycin
(state IV respiration) were also significantly higher in OxPhos-
DLBCLs compared with BCR-DLBCLs (Figure 7F). These results
provide a direct link between theOxPhos signature and an actual
quantitative increase in ETC activity in this DLBCL subset. More-
over, independent biochemical measurements of mitochondrial
complexes I, II, and IV in immunocapture assays provided
corroborative biochemical evidence for significant elevation of
these enzyme activities in OxPhos-DLBCLs (Figure S5B). In
aggregate, our observations both at the level of intact cells
(Figures 3A, 7A, and 7B) and isolated mitochondria (Figures 7F
and S5B) demonstrate that the OxPhos signature captures
a program of mitochondrial metabolism and energy transduction
that is selectively activated in this DLBCL subset.
The Relevance of ROS Content and Glutathione
Synthesis in DLBCL Subtypes
Mitochondria are a predominant source of ROS. While ROS
signaling is important for amyriad of cellular functions, excessive
mitochondrial superoxide can damage mitochondrial DNA,
modify proteins and lipids, and inhibit aconitase activity, thus
limiting oxidative phosphorylation. Elevated ETC activity in
OxPhos-DLBCL, particularly of complex I, predicted increased
accumulation of mitochondrial superoxide. However, MnSOD
is also concomitantly elevated in this subset (Figures 1, 2, and
S1A; Table S1), potentially as a mechanism to counteract
increased burden of mitochondrial superoxide. Efficient clear-
ance of ROS would also ensure that oxidative phosphorylationancer Cell 22, 547–560, October 16, 2012 ª2012 Elsevier Inc. 555
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Metabolism to Cellular ATP and Energy
Transduction in DLBCL Subsets
(A) Percent contribution of glycolysis and mito-
chondrial metabolism to total cellular ATP. For
each subtype, cumulative data from four OxPhos-
DLBCL (Karpas 422, OCI-Ly4, Pfeiffer, and
Toledo) and four BCR-DLBCL (SU-DHL-4, SU-
DHL-6, OCI-Ly1, andOCI-Ly7) cell lines are shown.
(B) Mitochondrial ATP synthesis rate. Cumulative
data from four OxPhos-DLBCL (red bar) and
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as in (A).
(C)Averagecopynumberof 110mitochondrial SNP
probes for 39OxPhos-DLBCL and 33BCR-DLBCL
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Whitney U test and found to be nonsignificant.
(D–F) OCR in isolated mitochondria in different
respiratory states. (D) Schematics of mitochon-
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traces in mitochondria isolated from DLBCL cell
lines indicating respiratory states examined as
described in the Supplemental Experimental
Procedures. (F) OCR in isolated mitochondria
measured using complex I- or complex II-linked
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See also Figure S5.
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Metabolic Fingerprints in DLBCL Molecular Subsetscould remain elevated in OxPhos-DLBCLs. Assessment of
mitochondrial superoxide using MitoSOX Red revealed lower
steady state levels in OxPhos-DLBCLs (Figure 8A). These ob-
servations were further integrated with the total cellular ROS
levels using CM-H2DCFDA, a fluorescent probe that is sensitive
to oxidation by peroxyl, alkoxyl, peroxynitrite, NO2_, CO3_, and
OH_ radicals and can thus serve as an indicator of overall
oxidative stress. The CM-H2DCFDA signal intensity was also
significantly lower in OxPhos-DLBCLs (Figure 8A). A potential
explanation for these observations is increased diversion of
peroxide generated from the SOD-catalyzed reaction into
the antioxidant glutathione (GSH) system. Consistent with
this possibility, GSH levels were significantly higher in OxPhos-
DLBCLs (Figure 8A), suggesting increased capacity for ROS
detoxification.
Given the quantitative differences in ROS and GSH content
in DLBCL cell lines, we hypothesized that the capacity to
maintain a large GSH pool may be required for the survival of556 Cancer Cell 22, 547–560, October 16, 2012 ª2012 Elsevier Inc.OxPhos-DLBCLs. To test this possibility,
de novo GSH synthesis was inhibited by
shRNA-mediated depletion of g-glutamyl
cysteine synthase (GCS), a rate-limiting
enzyme that catalyzes the introduction
of an amide linkage between the g-
carboxyl group of glutamate and cysteine
(Figure 8B). OxPhos-DLBCL cell lines
were significantly more sensitive to GCS
knockdown compared with the BCRsubset (Figures 8C and S6), suggesting that they may be more
reliant on GSH for survival.
DISCUSSION
Our integrative analysis using proteomics, mitochondrial
respirometry, and metabolomics have unraveled metabolic
distinctions in DLBCL subsets. We show that, compared with
non-OxPhos/BCR DLBCLs, nutrient and energy metabolism in
OxPhos-DLBCL have a significant mitochondrial component,
marked by elevated oxidative phosphorylation, increased con-
tribution of mitochondria to total cellular energy budget, greater
incorporation of fatty acid- and glucose-derived carbons into
the TCA cycle, and increased lipogenesis from these carbon
substrates. In comparison, the non-OxPhos DLBCLs have
greater glycolytic flux. These studies also provide a clear ex-
ample of heterogeneity in fuel utilization pathways even within
the same disease entity.
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Metabolic Fingerprints in DLBCL Molecular SubsetsThe differential utilization of glucose- and fatty-acid-derived
carbons in OxPhos versus non-OxPhos DLBCLs appears to
parallel the absence or presence of functional BCR signaling,
respectively. This is consistent with our observations that acute
inhibition of BCR signaling upon SYK depletion is sufficient to
enhance palmitate-induced mitochondrial OCR in BCR-DLBCL
cell lines. BCR-derived signals are critical for growth and survival
of mature B cells as well as multiple B cell lymphomas (Ku¨ppers,
2005). These signals also trigger glucose utilization in a PI3K-
dependent manner that is marked by an initial increase in lactate
production and a subsequent shift to the pentose phosphate
pathway during progression to S phase (Doughty et al., 2006).
Reduction in glycolytic flux and incorporation of glucose carbons
into the pentose pool in OxPhos compared with non-OxPhos
DLBCLs is consistent with published observations that
OxPhos-DLBCLs do not display the full phosphorylation pattern
of signaling intermediates following BCR crosslinking and are
insensitive to inhibitors of BCR signaling (Chen et al., 2008).CThe common metabolic profile of non-OxPhos DLBCLs is
striking, given that these tumors rely on multiple components
of BCR signaling (Chen et al., 2008; Compagno et al., 2009;
Davis et al., 2010). This may suggest that proliferation and
survival mechanisms in these tumors may converge on glycol-
ysis. The clear distinction between the metabolic profiles of
OxPhos- and BCR-DLBCLs suggests that the specific pattern
of nutrient metabolism in the former may provide an alternative
survival program independent of the BCR network. Moreover,
the OxPhos metabolic signature may have broader implications
for other tumor types that are independent or have lost depen-
dency on the components of BCR signaling.
Several independent approaches to inhibit the mitochon-
drial FAO program significantly compromised the survival of
OxPhos-DLBCL. Within this context, BrCA-mediated inhibition
of mitochondrial FAO and pharmacologic or genetic interference
with PPARg were selectively toxic to OxPhos-DLBCL. The rele-
vance of PPARg in multiple cancer models and the antitumorancer Cell 22, 547–560, October 16, 2012 ª2012 Elsevier Inc. 557
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Metabolic Fingerprints in DLBCL Molecular Subsetseffects of its inhibition have been reported (Burton et al., 2008).
Increased PPARg activity has been recently implicated in
differentiation and stimulation of antibody production in normal
human B-lymphocytes (Garcia-Bates et al., 2009). Whether this
is accompanied by increased FAO in normal lymphocytes
remains to be determined. Nevertheless, it is possible that the
metabolic signature in OxPhos-DLBCL represents pathways
relevant to B-lymphocytes that are further modified to fulfill
nutrient and energy requirements of these tumors.
Findings in other cancer models have suggested that FAO
may serve as an alternative survival pathway that is triggered
by glucose deprivation or lack of glucose uptake (Barger and
Plas, 2010; Schafer et al., 2009). Moreover, a recent report
showed increased FAO in solid tumors contributes to rapamycin
resistance (Zaugg et al., 2011). The survival-promoting effect of
fatty acid metabolism has also been reported in a leukemia
model (Samudio et al., 2010). In this model, increased fatty
acid metabolism was decoupled from oxidative phosphoryla-
tion, which appears to be distinct from enhanced ATP-coupled
OCR in response to palmitate in OxPhos-DLBCL.
Concomitant utilization of palmitate-derived acetyl-CoA for
ATP production and citrate synthesis in OxPhos-DLBCL
suggests that FAO and fatty acid synthesis may be concurrent
pathways in these cells. This may be surprising in light of the
inhibitory effect of citrate-derived malonyl-CoA on mitochondrial
transport of long-chain fatty acids through carnitine palmitoyl-
transferase (CPT)1. However, several possibilities may explain
these observations. The potency of inhibition by malonyl-CoA
differs between the two CPT1 isoforms and is likely further influ-
enced by their relative abundance (McGarry and Brown, 1997).
CPT1A is 80 fold less sensitive to malonyl-CoA than CPT1B
and the ratio of CPT1A to 1B expression is higher in OxPhos-
DLBCL. The relative abundance of CPT1A and the possibility
that malonyl-CoA may be used rapidly prior to its accumulation
may explain how mitochondrial FAO could proceed unhindered
in these cells. A scenario for rapid utilization of malonyl-CoA is
active fatty acid synthesis aswould be expected in a proliferating
cell. In addition, fatty acid synthesis may serve as a ‘‘sink’’ for
excess acetyl CoA/citrate generated due to enhanced FAO
and increased entry of acetyl-CoA into the TCA cycle. Concur-
rent FAO and fatty acid synthesis in other tumors has been
observed (Ookhtens and Baker, 1979; Ookhtens et al., 1984). It
is also interesting to note that increased FAO in acute myeloid
leukemia has been linked to a quiescent pool of tumor-initiating
cells (Samudio et al., 2010). The precise molecular basis for
concomitant use of fatty acids for ATP production and citrate
synthesis in OxPhos-DLBCL awaits future studies.
Parallel activation of an antioxidant defense mechanism with
increased mitochondrial FAO in OxPhos-DLBCL is intriguing.
A link between FAO and antioxidant capacity has been previ-
ously suggested. For example, mitochondrial FAO may serve
as a source of NADPH to regenerate GSH (Pike et al., 2011).
On the other hand, a reduced cellular redox state may be
important for completion of b-oxidation (Korge and Weiss,
2006; Schafer et al., 2009). It is also possible that elevated
GSH in OxPhos-DLBCL is secondary to its increased synthesis
from glutamate. This is consistent with higher enrichment of
fatty-acid-derived glutamate in this subtype. While increased
GSH and MnSOD levels are in agreement with lower ROS558 Cancer Cell 22, 547–560, October 16, 2012 ª2012 Elsevier Inc.content, additional mechanisms contributing to ROS handling
in OxPhos-DLBCL cannot be excluded.
Our findings provide functional validation of quantifiable
metabolic differences associated with transcriptionally defined
subsets of DLBCL. These observations also indicate that the
OxPhos molecular signature is a bona fide metabolic program
that is selectively activated in these lymphomas, providing
distinct growth and survival benefits. Detailed fingerprints of
the DLBCL metabolome may uncover important insights into
the molecular pathogenesis and underlying heterogeneity of
these lymphomas as well as additional road maps to subtype-
specific therapeutic targets.
EXPERIMENTAL PROCEDURES
Primary DLBCL Biopsies
Protein samples were prepared from frozen biopsy specimens of newly diag-
nosed, previously untreated primary DLBCLs with >80% tumor involvement
according to Institutional Review Board (IRB)-approved protocols from two
institutions (Brigham and Women’s Hospital and Dana-Farber Cancer Insti-
tute). A waiver to obtain informed consent was granted by the IRBs because
otherwise discarded tissue was used. The frozen biopsy specimens from
which total RNA and high-molecular-weight DNA were extracted for transcript
abundance and SNP analysis have been described in a recent study (Monti
et al., 2012).
Sample Preparation and Labeling for iTRAQ Analysis
Mitochondria isolated from DLBCL cell lines or Trizol-purified primary biopsy
proteins were solubilized in 7.2 M guanidine hydrochloride, 100 mM ammo-
nium bicarbonate. Protein concentration was determined by the Bradford
assay (Bio-Rad, Hercules, CA, USA), and equal amounts of protein were
reduced with 10 mM dithiothreitol (DTT) for 30 min at 56C and alkylated
with 22.5 mM iodoacetamide for 30 min at room temperature in the dark.
DTT was added to a final concentration of 20 mM to quench the remaining
iodoacetamide. Proteins were digested overnight with trypsin (1:20) at 37C
after addition of 100 mM ammonium bicarbonate solution to dilute the con-
centration of guanidine HCl to 1 M. Digests were acidified with 10% trifluoro-
acetic acid and desalted by C18. Aliquots of peptides were stored at 80C.
Mitochondria-derived peptides (50 mg) from three OxPhos (Karpas 422,
Toledo, and Pfeiffer) and three BCR (OCI-Ly1, SU-DHL-4, and SU-DHL-6)
cell lines were solubilized in 100 ml of 30% 500 mM triethylammonium bicar-
bonate, pH 8.5/70% ethanol, and 1 U of iTRAQ 8-plex reagent was added
to each sample (Karpas 422-113, Toledo-114, Pfeiffer-115, OCI-Ly1-117,
SU-DHL-4-118, SU-DHL-6-119; note that 116 and 121 reagents were not
used). The solution was incubated for 1 hr at room temperature, and the reac-
tions were combined and dried by vacuum centrifugation. Labeled peptides
were desalted by C18, dried again by vacuum centrifugation, and stored
at 80C. The same procedure was used to label 100-mg aliquots of primary
DLBCL biopsy-derived peptides with iTRAQ 4-plex reagent [biopsy #32
(OxPhos)-114; biopsy #39 (OxPhos)-115; biopsy #42 (BCR)-116)]. iTRAQ-
labeled peptide samples were analyzed and data processed as described
in Supplemental Experimental Procedures.
Mitochondrial Respirometry
OCR was measured in real time using the XF24 extracellular flux analyzer
instrument and the AKOS algorithm v1.5.069 software (Seahorse Bioscience
Inc., Chicopee, MA, USA). For whole cell studies, cells were seeded on XF24
V7 plates coated with Cell-Tak (BD Biosciences, Bedford, MA, USA) at 3 3
105 cells/well in 600 ml of sodium bicarbonate-free Roswell Park Memorial
Institute (RPMI) medium alone or supplemented with 10 mM glucose, 2 mM
glutamine or 0.2 mM palmitate. When palmitate was tested, 0.5 mM carnitine
was included in the incubation/equilibrationmedium to ensure import of bovine
serum albumin (BSA)-conjugated palmitate intomitochondria. The plates were
spun at 500 rpm (breaks off) and incubated at 37C for 10 min to ensure cell
attachment. Measurements were taken for a total of 60 min, including a
12 min incubation period prior to starting baseline measurements. Within this
Cancer Cell
Metabolic Fingerprints in DLBCL Molecular Subsetsassay time, OCR was measured for 3 min periods with 5 intervals between
measurements. After baseline measurements, 2.5 mM oligomycin was added
in a single 75 ml injection. In all experiments, parallel samples were run in the
absence of oligomycin to ensure stable baselines as a quality control param-
eter for the bioenergetics health of the cells. OCR in isolated mitochondria
was determined as detailed in the Supplemental Experimental Procedures.
13C Isotopomer-Based Metabolomics Analysis
Cells (10 3 106) were incubated for 8 hr at 37C in glutamine-free unbuffered
RPMI medium containing 10 mM malate, 0.5 mM carnitine, 10 mM b-hydrox-
ybutyrate, 10% (v/v) fetal bovine serum supplemented with 10 mM glucose,
4 mM glutamine, and 0.2 mM BSA-conjugated palmitate. When tracing
glucose or palmitate carbons, the media were supplemented with U-13C-
glucose or U-13C-palmitate isotopomers (Cambridge Isotope Laboratories,
Andover, MA, USA) to the final concentrations indicated above. Cell pellets
and 1 ml aliquots of media were frozen on dry ice and processed for LC-
MS/MS and gas chromatography/mass spectrometry (GC/MS) as detailed in
the Supplemental Experimental Procedures.
Mitochondrial Copy Number Analysis
The mitochondrial copy number was assessed using the mitochondrial SNP
probes within the Affymetrix HD-SNP array 6.0 data from an independent
series of primary DLBCL samples (Monti et al., 2012; GEO accession number
GSE34171). The presegmentation data processing was performed according
to the SNParray 6.0 analytical pipeline described elsewhere (Cancer Genome
Atlas Research Network, 2008). Gene expression profiling of the same
samples allowed assignment of consensus cluster subtypes (Monti et al.,
2012; GEO accession number GSE34171). Subsequently, the average copy
number of 110 mitochondrial SNP probes was computed and visualized using
a box plot for the 33 BCR and 39 OxPhos samples. Differences were tested
using a Mann-Whitney U test (Dawson-Saunders and Trapp, 1994).
Statistics
Unless otherwise indicated, statistical analysis was performed using two-
tailed Student’s t test, assuming unequal variance. Transcript abundance
was visualized with box plots (median, line; 25% and 75% quartile, box;
whiskers, minimum to maximum).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, three tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2012.08.014.
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